Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for Treatment of IDA in CKD Patients on Hemodialysis

NCT01227616 is registered in ClinicalTrials.gov with AMAG Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01227616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01227616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for Treatment of IDA in CKD Patients on Hemodialysis
Lead sponsor
AMAG Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2013
Completion date
February 28, 2017
Enrollment
296 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease(ckd), iron deficiency anemia treatment